A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy

Chloé B. Steen, Ellen Leich, June H. Myklebust, Sandra Lockmer, Jillian F. Wise, Björn E. Wahlin, Bjørn Østenstad, Knut Liestøl, Eva Kimby, Andreas Rosenwald, Erlend B. Smeland, Harald Holte, Ole Christian Lingjærde, and Marianne Brodtkorb

Disclosures: Janssen-Cilag: Advisory board (E.K., H.H.) and scientific lectures (E.K).

Contributions: B.E.W., B.Ø., C.B.S., E.K., H.H., S.L. and M.B. collected the data, B.Ø., C.B.S., E.B.S., E.K., H.H., O.C.L. and M.B. designed the research, A.R. and E.L. performed experiments and raw data analyses, C.B.S., K.L., O.C.L. and M.B. conceived and performed all analyses and made figures, C.B.S., E.B.S., H.H., J.H.M., J.F.W., O.C.L. and M.B. wrote the paper; and all authors contributed to the interpretation of data and have approved the final version of the manuscript.